# Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years

> **NCT02616783** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 167 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** E/C/F/TAF
- **DRUG:** TDF
- **DRUG:** FTC
- **DRUG:** FTC/TDF
- **DRUG:** 3TC
- **DRUG:** Third agent

## Key facts

- **NCT ID:** NCT02616783
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-22
- **Primary completion:** 2018-02-21
- **Final completion:** 2018-03-21
- **Target enrollment:** 167 (ACTUAL)
- **Last updated:** 2020-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02616783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02616783, "Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02616783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*